ArriVent BioPharma
(NASDAQ) AVBP
ArriVent BioPharma Financials at a Glance
Market Cap
$1.01B
Revenue (TTM)
$0.00
Net Income (TTM)
$166.31M
EPS (TTM)
$-4.46
P/E Ratio
-5.13
Dividend
$0.00
Beta (Volatility)
0.95 (Low)
Dividend
$0.00
Beta (Volatility)
0.95 (Low)
Price
$22.37
Volume
3,474
Open
$22.69
Price
$22.37
Volume
3,474
Open
$22.69
Previous Close
$22.86
Daily Range
$22.34 - $23.01
52-Week Range
$15.47 - $27.22
Dividend
$0.00
Beta (Volatility)
0.95 (Low)
Price
$22.37
Volume
3,474
Open
$22.69
Previous Close
$22.86
Daily Range
$22.34 - $23.01
52-Week Range
$15.47 - $27.22
AVBP News
AVBP: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout ArriVent BioPharma
Industry
Biotechnology
Sector
Health CareEmployees
77
CEO
Zheng Bin Yao, PhD
Website
www.arrivent.comHeadquarters
Newtown Square, 19073, US
AVBP Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-59%
Return on Capital
-58%
Return on Assets
-50%
Earnings Yield
-19.49%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.01B
Shares Outstanding
44.20M
Volume
3.47K
Short Interest
0.00%
Avg. Volume
481.99K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$177.53M
EBITDA
$177.53M
Operating Cash Flow
$160.59M
Capital Expenditure
$0.00
Free Cash Flow
$160.59M
Cash & ST Invst.
$312.82M
Total Debt
$14.00K
ArriVent BioPharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.01B
N/A
Market Cap/Employee
$19.43M
N/A
Employees
52
N/A
Net Income
$35.54M
-72.3%
EBITDA
$38.82M
-63.8%
Quarterly Fundamentals
Net Cash
$312.81M
+43.0%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$0.00
-100.0%
Short Term Debt
$14.00K
-91.4%
Return on Assets
-49.92%
N/A
Return on Invested Capital
-57.79%
N/A
Free Cash Flow
$30.66M
-89.8%
Operating Cash Flow
$30.66M
-89.8%